Cover Image
市場調查報告書

路易氏體失智症 - 開發平台分析

Lewy body Dementia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251635
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
路易氏體失智症 - 開發平台分析 Lewy body Dementia - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 48 Pages
簡介

路易氏體失智症是具有跟老年癡呆症和帕金森氏症共同特徵的癡呆症型態之一。所謂路易氏體是種團狀的蛋白質構造,沈積於在腦部的整個皮質以及深入至中腦及腦幹中的區域,會造成腦部正常功能漸漸低落。常見的症狀有幻視和異動症,認知障礙,以及憂鬱狀態。致病因素有年齡及家族病史等。治療有使用膽鹼酯酶抑製劑,抗精神病藥,帕金森氏病藥物等。

本報告提供路易氏體失智症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關最新的新聞和發表及開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

目錄

簡介

  • 調查範圍

路易氏體失智症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • BioArctic Neuroscience AB
  • ProteoTech, Inc.
  • 大日本住友製藥
  • Varinel, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BAN-0805
  • IIPP-1
  • PD-61W3
  • PD-61W3 Backup
  • VAR-10100
  • zonisamide

最近的開發平台趨勢

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8506IDB

Summary

Global Markets Direct's, 'Lewy body Dementia - Pipeline Review, H2 2016', provides an overview of the Lewy body Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lewy body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lewy body Dementia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia
  • The report reviews pipeline therapeutics for Lewy body Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lewy body Dementia therapeutics and enlists all their major and minor projects
  • The report assesses Lewy body Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lewy body Dementia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lewy body Dementia Overview
  • Therapeutics Development
    • Pipeline Products for Lewy body Dementia - Overview
  • Lewy body Dementia - Therapeutics under Development by Companies
  • Lewy body Dementia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Lewy body Dementia - Products under Development by Companies
  • Lewy body Dementia - Companies Involved in Therapeutics Development
    • Axovant Sciences Ltd.
    • BioArctic AB
    • Eisai Co., Ltd.
    • Immungenetics AG
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Takeda Pharmaceutical Company Limited
  • Lewy body Dementia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (donepezil hydrochloride + glycopyrrolate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (glycopyrrolate + rivastigmine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAN-0805 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-2027 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • intepirdine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nelotanserin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-071 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-915 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zonisamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lewy body Dementia - Dormant Projects
  • Lewy body Dementia - Product Development Milestones
    • Featured News & Press Releases
      • Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia
      • Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia
      • Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of Nelotanserin For Lewy Body Dementia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lewy body Dementia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Lewy body Dementia - Pipeline by Axovant Sciences Ltd., H2 2016
  • Lewy body Dementia - Pipeline by BioArctic AB, H2 2016
  • Lewy body Dementia - Pipeline by Eisai Co., Ltd., H2 2016
  • Lewy body Dementia - Pipeline by Immungenetics AG, H2 2016
  • Lewy body Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Lewy body Dementia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Lewy body Dementia - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Lewy body Dementia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top